Nevada passed a law last week instituting new reporting requirements for drug makers that manufacture insulin. Other states like New York and Maryland have also established requirements that pharmaceutical companies report price increases on certain drugs.
The law, S.B. 539, mandates that the Nevada Dept. of Health & Human Services make a list of prescription drugs that it deems “essential” to treat diabetes, along with the wholesale acquisition cost of each drug on the list.
Get the full story at our sister site, Drug Delivery Business News.
The post Nevada law takes aim at insulin makers and their pricing strategies appeared first on MassDevice.